Guardant Health, Inc. raised financial guidance for the full year of 2024. For the period, the company expects revenue excluding screening to be in the range of $675 to $685 million, representing growth of 20% to 21% compared to full year 2023 This compares to the prior range of $655 to $670 million, representing growth of 16% to 19%.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
29.56 USD | 0.00% |
|
-2.15% | +9.28% |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+9.28% | 3.62B | |
-39.38% | 8.28B | |
-1.48% | 2.24B | |
-22.85% | 1.94B | |
-18.07% | 1.72B | |
+10.53% | 962M | |
+17.17% | 734M | |
-9.17% | 690M | |
-33.88% | 477M | |
+2.58% | 298M |
- Stock Market
- Equities
- GH Stock
- News Guardant Health, Inc.
- Guardant Health, Inc. Raises Financial Guidance for the Full Year of 2024